Stock Traders Buy Large Volume of Gain Therapeutics Call Options (NASDAQ:GANX)

Key Points

• Traders significantly increased their interest in Gain Therapeutics, purchasing 9,011 call options, a rise of 1,971% over the average daily volume.
• Analyst ratings are mixed, with a consensus rating of "Moderate Buy" and an average target price of $7.86 based on recent reports from multiple research analysts.
• Gain Therapeutics reported a loss of ($0.19) earnings per share for the last quarter, missing analyst estimates, as the company continues to develop novel therapeutics through its Magellan platform.

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the target of unusually large options trading on Wednesday. Traders purchased 9,011 call options on the company. This represents an increase of 1,971% compared to the average daily volume of 435 call options.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $8.00 price objective on shares of Gain Therapeutics in a report on Monday, October 13th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Gain Therapeutics in a report on Wednesday, October 8th. Roth Capital reduced their price target on Gain Therapeutics from $7.00 to $6.00 and set a "buy" rating for the company in a research report on Wednesday, August 13th. Maxim Group increased their price target on Gain Therapeutics from $5.00 to $7.00 and gave the company a "buy" rating in a research report on Tuesday, October 7th. Finally, BTIG Research reissued a "buy" rating and set a $9.00 price target on shares of Gain Therapeutics in a research report on Wednesday, October 15th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $7.86.

Gain Therapeutics Stock Performance

Shares of GANX traded down $0.09 during mid-day trading on Wednesday, reaching $2.02. The company's stock had a trading volume of 297,294 shares, compared to its average volume of 378,190. Gain Therapeutics has a 1-year low of $1.41 and a 1-year high of $2.81. The stock has a market cap of $72.44 million, a P/E ratio of -3.20 and a beta of 0.11. The business has a 50-day simple moving average of $1.82 and a two-hundred day simple moving average of $1.79. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.09.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02). As a group, equities research analysts anticipate that Gain Therapeutics will post -1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Gain Therapeutics

A number of large investors have recently made changes to their positions in GANX. Dauntless Investment Group LLC bought a new position in shares of Gain Therapeutics during the first quarter worth approximately $240,000. Marshall Wace LLP increased its stake in shares of Gain Therapeutics by 41.0% during the second quarter. Marshall Wace LLP now owns 276,433 shares of the company's stock worth $498,000 after purchasing an additional 80,407 shares during the period. Kovitz Investment Group Partners LLC bought a new position in shares of Gain Therapeutics during the first quarter worth approximately $91,000. Finally, Geode Capital Management LLC increased its stake in shares of Gain Therapeutics by 2.9% during the second quarter. Geode Capital Management LLC now owns 290,462 shares of the company's stock worth $523,000 after purchasing an additional 8,251 shares during the period. Institutional investors own 11.97% of the company's stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.